成都圣诺生物科技股份有限公司独立董事 关于第四届董事会第九次会议相关事项的独立意见 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》等 法规以及《成都圣诺生物科技股份有限公司章程》《成都圣诺生物科技股份有限 公司独立董事制度》等公司制度的规定，我们作为成都圣诺生物科技股份有限公 司（以下简称"公司"）的独立董事，本着对公司及全体股东负责的态度，基于 审慎独立判断的立场，认真审阅了公司第四届董事会第九次会议的相关议案，现 发表独立意见如下： 一、《关于<公司 2023 年半年度募集资金存放与实际使用情况的专项报告> 的议案》的独立意见 经核查，我们认为公司 2023 年半年度募集资金的存放和使用符合《上海证 券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》等相关法律、法规及其他规范性文件和公司《募集资金管 理制度》的相关规定，募集资金通过专户存储和专项使用，公司所披露信息真实、 准确、完整，与募集资金的实际使用情况一致，不存在改变或变相改变募集资金 用途和损害股东利益的情形，不存在违规存放和使用募集资金的情形，因此，我 们一致同意本议案。 （本页以 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2023-048 成都圣诺生物科技股份有限公司 关于持股 5%以上股东减持股份计划公告 公司于近日收到股东乐普医疗出具的《关于股东减持计划的告知函》,因股 东自身资金需求，乐普医疗拟通过集中竞价、大宗交易的方式减持其持有的公司 股份合计不超过 2,912,000 股，即不超过公司总股本的 2.60%。拟通过集中竞价 方式减持的部分，自本公告披露之日起 15 个交易日之后的 3 个月内进行, 且任 意连续 90 个自然日内减持的股份总数不超过公司股份总数的 1%；拟通过大宗交 易方式减持的部分，自本公告披露之日起 3 个交易日之后的 3 个月内进行, 且任 意连续 90 个自然日内减持的股份总数不超过公司股份总数的 2%。 如遇派息、送股、转增股本、配股等除权除息事项，上述拟减持股份数量将 相应进行调整，但减持股份占公司总股本的比例不变。 现将具体情况公告如下： 一、减持主体的基本情况 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股 ...

证券代码：688117 证券简称：圣诺生物 公告编号:2023-049 成都圣诺生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 24 日(星期四) 上午 10:00-11:00 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 8 月 17 日(星期四)至 2023 年 8 月 23 日(星期三)下午 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 (snkj@snbiopharm.com)进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 成都圣诺生物科技股份有限公司（以下简称"公司"）将于 2023 年 8 月 18 日在上海证券交易所网站（www.sse.com.cn）披露公司《2023 年半年度报告》， 为便于广大投资 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2023-047 成都圣诺生物科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 成都圣诺生物科技股份有限公司（以下简称"公司"）股票于 2023 年 8 月 9 日、8 月 10 日和 8 月 11 日连续三个交易日内收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易 实时监控细则》（以下简称"《实时监控细则》"）的有关规定，属于股票交易 异常波动情形。 经公司自查，公司目前日常经营情况正常，未发生重大变化。经公司向 控股股东、实际控制人书面询证，截至本公告披露日，公司不存在应披露而未披 露的重大信息。 公司关注到，近期市场面对糖尿病和减重治疗药物利拉鲁肽、司美格鲁 肽有所关注。而公司利拉鲁肽及利拉鲁肽注射液仿制药项目在国内尚处于临床 I 期阶段、司美格鲁肽现处于临床前研究阶段，均处于研发投入期；公司利拉鲁原 料药 2015 年 10 月在美国 DMF 备案，目前尚无 ...

《关于成都圣诺生物科技股份有限公司股票交易异常波动 的询证函》的回函 致：成都圣诺生物科技股份有限公司 贵公司《关于成都圣诺生物科技股份有限公司股票交易异常波动的询证函》 已收悉，经本人认真自查核实，现就公司询证事项回复如下： 截至目前，作为贵公司实际控制人，本人不存在涉及贵公司应披露而未披露 的重大信息，不存在正在筹划重大资产重组、发行股份、上市公司收购、债务重 组、业务重组、资产剥离和资产注入等重大事项。 本人及一致行动人在公司股票异常波动期间，不存在买卖公司股票的行为。 特此回函。 （本页以下无正文） （本页无正文，为实际控制人《<关于成都圣诺生物科技股份有限公司股票 交易异常波动的询证函>的回函》之签署页。） 实际控制人: 2025年8月11日 《关于成都圣诺生物科技股份有限公司股票交易异常波动 的询证函》的回函 致：成都圣诺生物科技股份有限公司 贵公司《关于成都圣诺生物科技股份有限公司股票交易异常波动的询证函》 已收悉，经本人认真自查核实，现就公司询证事项回复如下： 截至目前，作为贵公司实际控制人，本人不存在涉及贵公司应披露而未披露 的重大信息，不存在正在筹划重大资产重组、发行股份、上市公司收购、债 ...

Financial Performance - The company reported a significant increase in revenue, reaching RMB 1.5 billion, representing a 20% year-over-year growth[17]. - The company's operating revenue for 2022 was CNY 395.72 million, an increase of 2.38% compared to CNY 386.53 million in 2021[23]. - The net profit attributable to shareholders for 2022 was CNY 64.48 million, reflecting a growth of 5.28% from CNY 61.25 million in 2021[23]. - The net cash flow from operating activities increased by 82.44% to CNY 95.62 million, primarily due to an increase in received payments and a reduction in market business expenses[25]. - The basic earnings per share for 2022 was CNY 0.81, down 4.71% from CNY 0.85 in 2021[25]. - The company reported a decrease in the net profit after deducting non-recurring gains and losses, which was CNY 56.60 million, down 2.59% from CNY 58.10 million in 2021[23]. - The company achieved a net profit of 6,596.58 CNY million from its main business operations in the reporting period[148]. Dividend and Capital Increase - The company plans to distribute a cash dividend of 2.50 CNY per 10 shares, totaling approximately 20 million CNY, which represents 31.02% of the net profit attributable to shareholders for 2022[6]. - The company will increase its share capital by 4 shares for every 10 shares held, resulting in a total increase of 32 million shares, changing the total share capital to 112 million shares[6]. - The board of directors has approved the profit distribution and capital increase plan, pending approval from the annual general meeting[7]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5]. - The company has confirmed that there are no violations of decision-making procedures for external guarantees[10]. - The company has stated that all board members can guarantee the authenticity, accuracy, and completeness of the annual report[10]. - The company has not reported any major discrepancies in governance compared to regulatory requirements[169]. - The company has not faced any penalties from securities regulatory authorities in the past three years, indicating compliance with regulations[189]. Research and Development - The company is investing in R&D, with a budget increase of 30% to enhance innovation capabilities[17]. - The company's R&D expenditure as a percentage of operating revenue rose to 6.50%, an increase of 1.76 percentage points from 4.74% in 2021[25]. - R&D expenses increased by 40.29% year-over-year, totaling ¥25,714,181.48, primarily due to the one-time evaluation of Loxisomab injection[73]. - The company has several ongoing projects, including Liraglutide, which has a total investment of ¥5,000 million and is currently in clinical trials[75]. - The company has developed 16 self-researched peptide raw materials, with 11 products receiving production licenses or activation records in the domestic market[47]. - The company is focusing on expanding its core technology team, with several key personnel holding significant positions[178]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[17]. - Market expansion plans include entering two new international markets by Q3 2023[17]. - The company is exploring potential acquisitions to strengthen its product portfolio, targeting a deal valued at approximately RMB 500 million[17]. - The company aims to improve operational efficiency, targeting a 15% reduction in production costs by the end of 2023[17]. - The company plans to enhance its competitive position in the peptide CDMO service sector and expand its product line in high-value peptide raw materials[129]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company faces risks related to the consistency evaluation of generic drugs, which could impact its competitive advantage if not completed within the required timeframe[90]. - The company is exposed to macroeconomic risks that could adversely affect its operating conditions and profitability due to global economic downturns[95]. Human Resources and Governance - The company has established a comprehensive human resources management system to enhance the capabilities of its technical and management teams[42]. - The total number of employees in the parent company and major subsidiaries is 879, with 411 in production, 304 in technical roles, and 127 in administration[200]. - The company maintained a transparent and effective performance evaluation and incentive mechanism, linking employee income to industry and company performance[168]. Product Development and Pipeline - The company has provided over 40 pharmaceutical research services for new drug development, with 1 product approved for commercialization and 18 innovative peptides entering clinical trials[37]. - The company is actively pursuing new product approvals, with several drugs already submitted for regulatory review, including a treatment for hereditary angioedema[76]. - The company has several products in various stages of development, including Liraglutide and Ecallantide, with some products currently under review and others having completed clinical trials[134]. Financial Management - The company’s financing activities generated a net cash flow of RMB 42.25 million, a decrease of 86.47% compared to RMB 312.20 million in the previous year[97]. - Cash and cash equivalents at the end of the period amounted to 372,122,126.73 yuan, representing 33.58% of total assets, an increase of 75.89% from the previous period[117]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 6.4452 million RMB[187]. Strategic Initiatives - The company plans to focus on high-demand therapeutic areas such as oncology, diabetes, and gastrointestinal diseases, enhancing its R&D capabilities to maintain competitive advantages[156]. - The company intends to leverage its capital platform to explore potential investment opportunities and enhance its market competitiveness[158]. - The company is committed to increasing its R&D investment to develop high-tech, safe, and stable peptide drugs[152].

Financial Performance - The company's operating revenue for Q1 2023 was ¥81,516,580.85, representing a year-on-year increase of 0.96%[5]. - The net profit attributable to shareholders decreased by 1.82% to ¥14,032,925.44, while the net profit after deducting non-recurring gains and losses dropped significantly by 48.25% to ¥6,278,006.01[5][8]. - Total revenue for Q1 2023 was CNY 81,516,580.85, a slight increase of 1.0% compared to CNY 80,744,800.39 in Q4 2022[19]. - Net profit for Q1 2023 was CNY 14,032,925.44, a decrease of 1.8% from CNY 14,292,867.60 in Q4 2022[19]. - The net profit attributable to the parent company for Q1 2023 is CNY 14,032,925.44, compared to CNY 14,292,867.60 in Q1 2022, indicating a slight decrease[20]. - The total comprehensive income attributable to the parent company for Q1 2023 is CNY 14,032,925.44, down from CNY 14,292,867.60 in the same period last year[20]. - The basic and diluted earnings per share for Q1 2023 remain at CNY 0.18, unchanged from Q1 2022[20]. Cash Flow - The net cash flow from operating activities fell by 41.72% to ¥17,230,314.83, attributed to reduced sales collections and increased employee compensation payments[5][8]. - Cash inflows from operating activities for Q1 2023 amount to CNY 229,885,043.78, an increase from CNY 156,155,336.62 in Q1 2022[22]. - The net cash flow from operating activities for Q1 2023 is CNY 17,230,314.83, down from CNY 29,565,224.06 in Q1 2022[22]. - The net cash flow from investing activities for Q1 2023 is -CNY 175,165,401.28, compared to a positive CNY 19,110,356.37 in Q1 2022[23]. - Cash inflows from financing activities for Q1 2023 total CNY 140,000,000.00, significantly higher than CNY 10,000,000.00 in Q1 2022[23]. - The net cash flow from financing activities for Q1 2023 is CNY 127,206,627.92, compared to CNY 9,391,908.39 in Q1 2022[23]. - The ending cash and cash equivalents balance for Q1 2023 is CNY 340,592,596.07, up from CNY 268,158,720.07 at the end of Q1 2022[23]. - The company received CNY 1,439,471.11 in tax refunds during Q1 2023, compared to CNY 77,628.60 in Q1 2022[22]. Assets and Liabilities - The total assets at the end of the reporting period increased by 13.38% to ¥1,256,249,613.62 compared to the end of the previous year[6]. - Total assets increased to CNY 1,256,249,613.62, up from CNY 1,108,008,638.28, reflecting a growth of 13.4%[16]. - Total liabilities rose to CNY 415,445,853.87, an increase of 47.7% compared to CNY 281,271,366.55 in Q4 2022[16]. - The company’s total equity increased to CNY 840,803,759.75 from CNY 826,737,271.73, reflecting a growth of 1.7%[16]. - Long-term borrowings increased significantly to CNY 179,186,416.42 from CNY 48,052,800.00, indicating a strategic shift in financing[16]. Research and Development - The company's R&D investment totaled ¥6,158,199.18, accounting for 7.55% of operating revenue, a slight decrease of 0.01 percentage points[6]. - Research and development expenses for Q1 2023 were CNY 4,862,883.56, slightly down from CNY 5,112,082.43 in Q4 2022[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,815[10]. - Chengdu Sainuo Investment Co., Ltd. held 37.50% of the shares, making it the largest shareholder[10]. Other Information - The company did not disclose any new product developments or market expansion strategies during the reporting period[12]. - The company reported non-recurring gains of ¥7,754,919.43, primarily from government subsidies and other income[7]. - Cash and cash equivalents decreased to CNY 340,592,596.07 from CNY 372,122,126.73, representing a decline of 8.5%[14]. - The company reported a significant increase in inventory, which rose to CNY 159,832,819.20 from CNY 135,434,477.07, marking an increase of 18.0%[14].

证券代码：688117 证券简称：圣诺生物 公告编号：2023-013 成都圣诺生物科技股份有限公司 关于召开 2022 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址 http://roadshow.sseinfo.com/） 本次投资者说明会以网络文字互动形式召开，公司将针对 2022 年年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开时间、地点 （一）会议召开时间：2023 年 5 月 4 日（星期四）上午 10:00-11:00 会议召开方式：上证路演中心网络文字互动 投资者可以于 2023 年 4 月 24 日(星期一)至 2023 年 4 月 28 日(星期五) 下午 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱（snkj@snbiopharm.com）进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 成都圣诺生物科技股份有限公司（以 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company reported a revenue of RMB 100 million for the first half of 2022, reflecting a year-on-year growth of 20%[12]. - The company has provided a revenue guidance of RMB 250 million for the full year 2022, representing a projected growth of 25%[12]. - The company reported a total revenue of 17,410.00 million RMB, with a net profit of 1,737.19 million RMB for the first half of 2022[65]. - The company reported a total revenue of 22,266.21 million with a net profit of 2,783.9 million for the first half of 2022[97]. - The company's operating revenue for the first half of the year was RMB 167.51 million, a decrease of 13.49% compared to the same period last year[21]. - Net profit attributable to shareholders was RMB 18.64 million, down 22.36% year-on-year, while the net profit after deducting non-recurring gains and losses was RMB 14.98 million, a decrease of 34.29%[21]. - Basic and diluted earnings per share were both RMB 0.23, reflecting a decline of 39.47% compared to the previous year[22]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users by the end of June 2022[1]. - User data indicates an increase in active users by 15% compared to the previous period, reaching a total of 1.5 million active users[12]. - The company expects a revenue growth forecast of 25% for the second half of 2022, driven by new product launches and market expansion strategies[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[12]. Research and Development - Investment in R&D increased by 30% compared to the previous year, focusing on innovative drug development and technology enhancements[1]. - The company has invested RMB 50 million in R&D for new technologies, focusing on peptide-based drugs[12]. - Research and development expenses increased by 120.57% year-on-year, amounting to RMB 16.01 million, which impacted profitability[21]. - The proportion of R&D investment to operating revenue rose to 10.37%, an increase of 5.93 percentage points compared to the previous year[21]. - The total R&D investment increased by 102.18% year-on-year, reaching ¥17,371,595.03, driven by increased costs for the consistency evaluation of the project for Liraglutide injection and the initiation of the calcitonin project[57]. - The number of R&D personnel increased to 149, representing 19.68% of the total workforce[67]. - The company has 10 R&D products submitted for registration with the National Medical Products Administration, with 15 additional projects in mid to long-term research[70]. Product Development and Innovation - The company has launched two new products in Q2 2022, contributing to 15% of total sales during the period[1]. - The company has launched a new product line aimed at Type 2 diabetes patients, projected to generate RMB 30 million in revenue within the first year[12]. - The company is currently in the clinical trial phase for three new drugs, with expected completion of Phase III trials by Q4 2022[12]. - The company is actively involved in clinical research for various new drugs, including peptide injections for diabetes and cardiovascular diseases[32]. - The company has achieved significant milestones in the registration and approval of its products in both domestic and international markets[30]. - The company is committed to ongoing research and development to support its growth strategy and meet market demands[30]. Strategic Acquisitions and Partnerships - A strategic acquisition of a biotech firm is in progress, expected to enhance the company's product pipeline and market capabilities[1]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio, with a budget of RMB 200 million allocated for this purpose[12]. - The company has established partnerships with well-known pharmaceutical enterprises such as Fresenius, Aurobindo, and others, with raw material products sold in Europe, the United States, India, and South Korea[34]. - The company is exploring partnerships to enhance its research capabilities and accelerate the development of new therapies[64]. Financial Integrity and Compliance - The company has no non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[1]. - The company has received FDA approval for multiple products, including Linaclotide for treating constipation and Degarelix for advanced prostate cancer, with production values of 780.00 million RMB and 2,000.00 million RMB respectively[63]. - The company emphasizes compliance with environmental regulations, indicating a commitment to sustainability[106]. - The company has established a commitment to ensure that any share reduction does not exceed 2% of the total shares within a 90-day period if conducted through block trades[127]. Environmental Management - The company has established a dedicated environmental health and safety management department to effectively manage pollutants generated during production[110]. - The company has implemented strict management systems for solid waste and self-monitoring to minimize environmental impact[110]. - The company has constructed a wastewater treatment facility to ensure compliance with standards before discharging into municipal systems[119]. - The company has received environmental impact approvals for multiple projects, including peptide drug production lines and new drug research initiatives[114]. Shareholder Commitments and Regulations - The company has committed to a share lock-up period of 36 months from the date of listing, during which no shares will be transferred or managed by others[126]. - The actual controllers, Wen Yongjun and Ma Lanwen, have also agreed to a similar 36-month lock-up period for their shares[129]. - The company will comply with relevant regulations regarding share transfers and reductions as stipulated by the China Securities Regulatory Commission and the Shanghai Stock Exchange[129]. - Shareholders holding more than 5% of the company's shares are prohibited from transferring their shares within 12 months of the company's listing[135].

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion for the fiscal year 2021, representing a growth of 25% compared to the previous year[18]. - The company reported a net profit of RMB 300 million, which is a 30% increase compared to the previous fiscal year[18]. - The company achieved operating revenue of CNY 386.53 million in 2021, representing a year-on-year growth of 2.05%[26]. - The net profit attributable to shareholders of the listed company was CNY 61.25 million, an increase of 2.09% compared to the previous year[26]. - The company reported a total revenue of 2,000.00 million for the year, with a growth rate of 52.88% compared to the previous year[85]. - The company reported a revenue of 1.2 billion in 2021, representing a year-over-year growth of 15%[180]. - The company provided a revenue guidance of 1.8 billion RMB for the next fiscal year, which reflects an expected growth of 20%[187]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 3 per 10 shares, totaling an estimated cash dividend of RMB 24 million, which represents 39.18% of the net profit attributable to shareholders for 2021[7]. - The profit distribution plan is subject to approval at the company's annual general meeting, highlighting the need for shareholder consent before implementation[8]. - The company confirmed the proposal for the distribution of profits for the year 2020 during the annual shareholder meeting[171]. Research and Development - The company focused on expanding its CDMO services and enhancing overseas business development during the reporting period[39]. - The company has developed core technologies in peptide drug CDMO services, including "single sulfur ring peptide large-scale production" and "long-chain peptide coupling technology" to enhance its market competitiveness in innovative drugs[40]. - The company is committed to ongoing research and development of new technologies and products to address unmet medical needs in various therapeutic areas[54]. - The company has established a robust pipeline of products in various stages of development, indicating strong future growth potential in the pharmaceutical market[54]. - The total R&D investment for the year was approximately ¥18.33 million, a decrease of 18.49% compared to the previous year[80]. - R&D investment accounted for 4.74% of total revenue, with a capitalization ratio of 25%[145]. Market Expansion and Strategy - The company is expanding its market presence, targeting an increase in market share by 10% in the Asia-Pacific region over the next two years[18]. - The company is exploring new strategies for market expansion, including potential mergers and acquisitions to enhance its product offerings and market reach[54]. - Market expansion plans include entering three new international markets by the end of 2022[182]. - The company aims to strengthen its product development and technology platform, focusing on key areas such as oncology, diabetes, obstetrics, digestive system, and immune system diseases[157]. Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties, indicating a stable governance structure[11]. - The company has not violated decision-making procedures for external guarantees, reinforcing its compliance with regulations[11]. - The company maintained compliance with legal and regulatory requirements in all shareholder meetings[172]. - The company has not engaged in any related party transactions during the reporting period[174]. Risks and Challenges - The company has outlined various risks in its operations and has provided measures to address these risks, emphasizing the importance of investor awareness[5]. - The report includes a forward-looking statement risk declaration, cautioning investors about the uncertainties in future plans and strategies[10]. - The company faces risks related to research and development failures, which could lead to loss of competitive advantage if products do not meet regulatory approval[98]. - The company is exposed to financial risks, including potential issues with accounts receivable collection and foreign exchange fluctuations due to international operations[100]. Operational Efficiency - The gross margin improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[18]. - The company has successfully reduced operational costs by 15% through efficiency improvements in the supply chain[187]. - The company reported a significant increase in technical service costs, which rose by 22.65% year-on-year to 1.97 million RMB[113]. Shareholder Engagement - The company held a total of 3 shareholder meetings during the reporting period, including 1 annual meeting and 2 extraordinary meetings[172]. - The board of directors and senior management did not experience any changes in shareholding during the reporting period, with all key personnel maintaining their shareholdings[174]. - The total pre-tax remuneration for the chairman and general manager, Wen Yongjun, was 640,800 RMB[174].